SCHEMBL3592343

SCHEMBL3592343

Cc1ccc(-c2cc(-c3cc(O)c(O)c([N+](=O)[O-])c3)no2)c(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 2/20 0.43
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
TP53 P04637 1/20 0.40
CTSB P07858 1/20 0.37
CTSH P09668 1/20 0.37
MAPT P10636 4/20 0.36
PTPN1 P18031 1/20 0.36
GPR35 Q9HC97 4/20 0.36
ERN1 O75460 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2C9 P11712 3/20 0.36
HPGD P15428 3/20 0.36
NFKB1 P19838 2/20 0.36
CYP2C19 P33261 2/20 0.36
NFKB2 Q00653 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586634 0.88 COMT (0.46) COMTNPC1RAB9AMEN1KMT2A
SCHEMBL3592774 0.84 COMT (0.55) COMTNPC1RAB9AMAPTHPGD
SCHEMBL3582061 0.83 COMT (0.52) COMTNPC1RAB9ATP53MAPT
SCHEMBL3582058 0.83 EIF4E (0.43)
SCHEMBL3597205 0.82 COMT (0.40) COMTMEN1KMT2ACTSBCTSH
SCHEMBL1447525 0.81 COMT (0.46) COMTNPC1RAB9AMEN1KMT2A
SCHEMBL3589121 0.81 COMT (0.41) COMTNPC1RAB9AMEN1KMT2A
SCHEMBL3595352 0.80 COMT (0.43) COMTNPC1RAB9AMEN1KMT2A
SCHEMBL3586367 0.79 TUBB4A (0.41) COMTMEN1KMT2ACTSBCTSH
SCHEMBL3583954 0.79 COMT (0.47) COMTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 COMT 10/4885NPC1 90/4885RAB9A 2812/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 COMT 10/4885NPC1 90/4885RAB9A 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.